Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A life-threatening condition that can potentially complicate pregnancy. It is named for 3 features of the condition: H emolysis, E levated L iver enzyme levels, and L ow P latelet levels. It typically occurs in the last 3 months of pregnancy (the third trimester) but can also start soon after delivery. A wide range of non-specific symptoms may be present in women with HELLP syndrome. Symptoms may include fatigue; malaise; fluid retention and excess weight gain; headache; nausea and vomiting; pain in the upper right or middle of the abdomen; blurry vision; and rarely, nosebleed or seizures. The cause of HELLP syndrome is not known, but certain risk factors have been associated with the condition. It is most common in women with preeclampsia or eclampsia. If not diagnosed and treated quickly, HELLP syndrome can lead to serious complications for the mother and baby.The main treatment is to deliver the baby as soon as possible, even if premature. Treatment may also include medications needed for the mother or baby, and blood transfusion for severe bleeding problems.
Features include always present findings: Low platelet count (thrombocytopenia) and Elevated circulating hepatic transaminase concentration; and very common findings: Red blood cell destruction (hemolytic anemia). 29 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 6 | Low platelet count (thrombocytopenia), Red blood cell destruction (hemolytic anemia), Microangiopathic hemolytic anemia |
Biomarker and diagnostic research for HELLP syndrome has been reported in the published literature.
Phenotype severity distribution: 2 always present features, 1 very common feature, 7 common features.
Estimated prevalence: Unknown (Unknown prevalence).
10 clinical trials registered, 4 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 1 PHASE4, 1 PHASE3, 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05500989](https://clinicaltrials.gov/study/NCT05500989) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:30 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about HELLP syndrome
Digestive system | 4 | Elevated circulating hepatic transaminase concentration, Vomiting, Nausea |
Brain and nerves | 3 | Headache, Fatigue, Cerebral hemorrhage |
Lab test results | 2 | Elevated circulating hepatic transaminase concentration, Elevated LDH (tissue damage marker) (increased circulating lactate dehydrogenase concentration) |
Kidneys and urinary system | 2 | Protein in the urine (proteinuria), Acute kidney injury |
Lungs and breathing | 2 | Pleural effusion, Pulmonary edema |
PlacEntal Acute Atherosis RefLecting Subclinical Atherosclerosis
— |
Maastricht University Medical Center |
RECRUITING |
[NCT07151339](https://clinicaltrials.gov/study/NCT07151339) | Pilot Project Renal and Cardiovascular Tertiary Prevention in Preeclampsia | — | University Hospital Schleswig-Holstein | RECRUITING |
[NCT06377878](https://clinicaltrials.gov/study/NCT06377878) | The Preeclampsia Registry | — | Preeclampsia Foundation | RECRUITING |
[NCT07810439](https://clinicaltrials.gov/study/NCT07810439) | PROTECT-Africa: Biomarker Validation for Preeclampsia Triage | — | Africa Clinical Research Network (ACRN) | RECRUITING |
250 publications have been identified in PubMed for HELLP syndrome. Kisho has analyzed 166 by research type. Research spans Case Report / Case Series (28%), Epidemiology / Natural History (24%), and Review / Meta-Analysis (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 47 | 28% |
Disease patterns and progression | 40 | 24% |
Research summaries | 34 | 20% |
Testing and diagnosis research | 15 | 9% |
Laboratory research | 15 | 9% |
Clinical study results | 12 | 7% |
Other research | 3 | 2% |
Colacurci D (2026). [PMID: 42082345](https://pubmed.ncbi.nlm.nih.gov/42082345/). *J Clin Hypertens (Greenwich)*. [Review / Meta-Analysis]
Nakagawa K (2026). [PMID: 41442822](https://pubmed.ncbi.nlm.nih.gov/41442822/). *Journal of reproductive immunology*. [Epidemiology / Natural History]
Anteby M (2026). [PMID: 42101016](https://pubmed.ncbi.nlm.nih.gov/42101016/). *Int J Gynaecol Obstet*. [Epidemiology / Natural History]
Sun C (2026). [PMID: 42165172](https://pubmed.ncbi.nlm.nih.gov/42165172/). *J Clin Hypertens (Greenwich)*. [Epidemiology / Natural History]
Bahar A (2026). [PMID: 41838256](https://pubmed.ncbi.nlm.nih.gov/41838256/). *Molecular biology reports*. [Review / Meta-Analysis]
Goshu MT (2026). [PMID: 42057011](https://pubmed.ncbi.nlm.nih.gov/42057011/). *BMC Pregnancy Childbirth*. [Case Report / Case Series]
Scioscia M (2026). [PMID: 41950817](https://pubmed.ncbi.nlm.nih.gov/41950817/). *J Reprod Immunol*. [Review / Meta-Analysis]
Kamidani R (2026). [PMID: 42070386](https://pubmed.ncbi.nlm.nih.gov/42070386/). *Thromb Res*. [Review / Meta-Analysis]
Xia T (2026). [PMID: 41626101](https://pubmed.ncbi.nlm.nih.gov/41626101/). *Clinical case reports*. [Case Report / Case Series]
Frolkis A (2026). [PMID: 42027078](https://pubmed.ncbi.nlm.nih.gov/42027078/). *Turk J Gastroenterol*. [Review / Meta-Analysis]